Thorgeirsson G, Rudolph S A
Biochem Biophys Res Commun. 1984 Jun 15;121(2):657-63. doi: 10.1016/0006-291x(84)90232-8.
The phenothiazine thioridazine enhances the binding of [3H]-nitrendipine to cardiac membranes and antagonizes the inhibition of [3H]-nitrendipine binding by other classes of calcium channel blockers. These effects are similar to those of diltiazem. The increased binding of [3H]-nitrendipine in the presence of thioridazine or diltiazem is due to increased binding affinity rather than an increased number of binding sites. Increased affinity is due in part to a decrease in the dissociation rate of nitrendipine in the presence of either thioridazine or diltiazem. Thioridazine also reverses the blocking effect of tiapamil (a phenylalkylamine) on [3H]-nitrendipine binding to rat heart membranes, as does diltiazem, suggesting that thioridazine binds to the same site as diltiazem. Thioridazine may have calcium channel blocking effects in the high therapeutic and toxic dose ranges that could be responsible for some of its adverse cardiovascular effects.
吩噻嗪类药物硫利达嗪可增强[3H]-尼群地平与心肌膜的结合,并拮抗其他类钙通道阻滞剂对[3H]-尼群地平结合的抑制作用。这些作用与地尔硫䓬相似。在硫利达嗪或地尔硫䓬存在的情况下,[3H]-尼群地平结合增加是由于结合亲和力增加而非结合位点数量增加。亲和力增加部分是由于在硫利达嗪或地尔硫䓬存在时尼群地平解离速率降低。硫利达嗪还可逆转替帕米(一种苯烷基胺)对[3H]-尼群地平与大鼠心肌膜结合的阻断作用,地尔硫䓬也有此作用,这表明硫利达嗪与地尔硫䓬结合于同一部位。硫利达嗪在高治疗剂量和中毒剂量范围内可能具有钙通道阻滞作用,这可能是其一些心血管不良反应的原因。